Core Insights - The article discusses the launch of Boltz-2, an open-source biomolecular foundation model developed by MIT and Recursion, which significantly improves the accuracy and speed of predicting molecular binding affinities and structures [1][2][5]. Company and Industry Overview - Boltz-2 is a pioneering model that combines structure and binding affinity prediction, achieving near-physics-based accuracy while being over 1,000 times faster than traditional methods [5][6]. - The model is designed to enhance drug discovery processes by allowing researchers to select promising molecules more effectively, thereby improving the success rates of R&D programs [3][4]. - The open-source nature of Boltz-2, including its training code, enables scientists to customize the model for specific molecules, facilitating broader applications in both academic and commercial settings [2][4]. - Recursion, the TechBio company behind Boltz-2, utilizes advanced machine learning algorithms and operates one of the world's most powerful supercomputers, BioHive-2, to support its mission of decoding biology for improved healthcare outcomes [7][8]. - The development of Boltz-2 involved collaboration between MIT's academic expertise and Recursion's AI capabilities, highlighting the importance of partnerships in advancing biotechnological innovations [3][5].

Virology - Respiratory Syncytial Virus (RSV) - Zelicapavir (EDP-938) is the only N-inhibitor in clinical development for RSV, with Phase 2 pediatric study complete and Phase 2 high-risk adult study ongoing[17, 6] - In a Phase 2 pediatric study, zelicapavir showed a viral load decline of 0.88 log at Day 3 and 1.18 log at Day 5 in the prespecified mITT-3 population[25] - EDP-323, an RSV L-protein inhibitor, demonstrated 85-87% reduction in viral load AUC in a human challenge model[42] - A Phase 2 high-risk adult study is designed to show a clinically meaningful reduction in symptom duration of at least ~1 day with Zelicapavir[37] Immunology - The company is developing a KIT inhibitor for mast cell driven diseases like Chronic Spontaneous Urticaria (CSU) and a STAT6 inhibitor for type 2 immune diseases like atopic dermatitis[6] - EPS-1421, a KIT inhibitor development candidate, inhibits KIT with nanomolar potency and demonstrates sub-nanomolar activity in vivo[63] - Prototype STAT6 inhibitors inhibit STAT6 with nanomolar potency and are highly selective for STAT6 versus other STATs[79] - Prototype STAT6 oral inhibitor results in complete inhibition of pSTAT6 in a mouse model[89] Financial Status - The company had $193.4 million in cash as of March 31, 2025[6] Business Development - The company plans to pursue partnerships for zelicapavir and/or EDP-323[102]

Core Insights - C4X Discovery Holdings Ltd has received an €8 million milestone payment from Sanofi due to progress in its oral IL-17A inhibitor program [1][2] - The total potential milestone payments from the license agreement with Sanofi could reach €414 million, including royalties on future net sales [2] - The oral IL-17A inhibitor aims to treat inflammatory diseases, representing a significant market opportunity [3] Company Developments - C4X Discovery has now received a total of €18 million in upfront and pre-clinical payments from Sanofi [2] - The CEO of C4X Discovery highlighted the importance of this milestone as a recognition of the company's drug discovery capabilities [4] - The Chairman noted the progress of the oral IL-17A inhibitor program reflects the growing value of C4X's broader pipeline, which includes multiple partnered and high-value programs [4] Industry Context - The IL-17A inhibitor program targets a multi-billion-dollar market for inflammatory disease treatments, providing an oral alternative to current injectable biologic therapies [3] - C4X Discovery's approach combines scientific expertise with advanced technologies to develop small molecule drug candidates for immuno-inflammation [6]

Core Investment Insights - NVIDIA's largest 13F holding is CoreWeave, accounting for 78% of its total reported 13F holdings in Q1, with NVIDIA owning approximately 7% of CoreWeave [4][5] - CoreWeave has seen a 169% increase in stock price since going public in March, largely due to its relationship with NVIDIA [5] Other Significant Holdings - The next largest holdings are Arm and Applied Digital, representing around 10% and 4% of NVIDIA's total $1.15 billion 13F portfolio respectively [6] - NVIDIA attempted to acquire Arm for $40 billion in 2020, but the deal fell through due to regulatory issues [6] - Applied Digital, which rents out computing power, has seen its stock decline approximately 1% since NVIDIA first reported owning it [8][9] AI and Drug Research Investments - Recursion Pharmaceuticals is NVIDIA's fourth largest holding, focusing on AI to accelerate drug discovery, but has not yet generated significant revenue [11] - Recursion's stock is down 51% since NVIDIA's initial investment announcement, despite a 24% jump on the day of the announcement [12] Emerging Companies in AI Computing - Nebius Group and WeRide each make up around 2% of NVIDIA's portfolio, with Nebius reporting a 385% increase in sales in Q1 [13][14] - WeRide operates autonomous driving platforms in China, utilizing NVIDIA's advanced chips [14] Investment Strategy and Market Perception - All companies in NVIDIA's 13F holdings are either customers or suppliers, indicating NVIDIA's deep understanding of their businesses [16] - While NVIDIA's investment is seen as a positive signal, it does not guarantee success for these stocks, as their prices can be volatile [16][17]

Core Viewpoint - Regeneron Pharmaceuticals has successfully bid for the majority of assets of 23andMe Holding Co. in a bankruptcy auction, planning to acquire key business units for $256 million [1][2]. Company Acquisition Details - Regeneron intends to acquire 23andMe's Personal Genome Service, Total Health and Research Services business units, Biobank, and related assets, while 23andMe will become a wholly-owned subsidiary of Regeneron [2]. - The acquisition does not include 23andMe's Lemonaid Health business [2]. - The deal is subject to bankruptcy court approval, regulatory clearances, and other customary closing conditions, with completion expected in Q3 2025 [3]. Strategic Benefits - The acquisition is expected to enhance Regeneron's genetics-based drug discovery efforts by integrating 23andMe's consumer genomic services with its research capabilities [6]. - Regeneron aims to leverage the acquired genetic data to drive drug discovery and development, particularly in areas such as cancer, infectious diseases, and immune disorders [4][6]. Commitment to Privacy - Regeneron has committed to maintaining 23andMe's consumer privacy standards and complying with data protection laws, ensuring transparency regarding the use of customer data [7].

Pioneering Drug Discovery FY 2024 & Strategic Review Disclaimer This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the "Company", "we," "our" or "us"). This presentation is made pursuant to Section 5(d) and/or Rule 163B of the Securities Act of 1933, as amended, and is intended solely for investors that are qualified institutional buyers or certain i ...

Core Insights - Google DeepMind has invested in Isomorphic Labs, an AI life sciences startup focused on drug discovery using AlphaFold technology, aiming to "solve all disease" through AI-powered methods [2][4][5] Company Overview - Isomorphic Labs was spun out of Google DeepMind after significant advancements in AI, particularly with AlphaFold2, which predicts protein structures and has the potential to revolutionize drug discovery [2][4][14] - The company has grown to over 200 employees and established partnerships with major pharmaceutical firms like Eli Lilly and Novartis, with potential partnership values nearing $3 billion [9][26] Investment and Funding - Google initially invested in Isomorphic in November 2021, although the amount remains undisclosed. Recently, Isomorphic secured $600 million in external funding led by Thrive Capital [6][8] - The funding will be used to expand into biologics and enhance computational capabilities necessary for AI applications in drug discovery [25][27] Market Potential - The drug discovery market is projected to reach $71 billion by 2025, with AI expected to significantly alter the landscape [7] - Traditional drug development processes can take over 10 years and cost more than $2 billion, but AI could streamline these processes, reducing costs and increasing success rates [8] Technological Advancements - Isomorphic has made AlphaFold3 available for non-commercial use, expanding its capabilities to predict structures of various biological molecules beyond proteins [10][12] - The company is focused on utilizing AlphaFold3 to enhance drug discovery and biological understanding, particularly in cancer and immunology [26][27] Leadership and Vision - Demis Hassabis, co-founder of DeepMind and now CEO of Isomorphic, emphasizes the importance of AI in improving human health and solving complex biological challenges [24][25] - The leadership team at Isomorphic is committed to fostering an interdisciplinary culture that combines AI expertise with drug discovery knowledge [18][28]

Core Insights - NVIDIA, Alphabet, and Google are launching new initiatives to enhance AI, democratize access to AI tools, and transform various industries including healthcare, manufacturing, and energy [1][20] Group 1: AI and Robotics Development - Engineers and researchers from Alphabet and NVIDIA are collaborating to develop robots with advanced grasping skills and reimagine drug discovery using AI and simulation technologies [2] - The partnership includes the use of NVIDIA platforms such as Omniverse™, Cosmos™, and Isaac™ to support these initiatives [2] - Intrinsic, an Alphabet company, is focused on creating adaptive AI for robotics, aiming to reduce the complexity and cost of programming industrial robots [9][10] Group 2: Drug Discovery Innovations - Isomorphic Labs is leveraging AI to revolutionize drug discovery, utilizing a state-of-the-art drug design engine on Google Cloud powered by NVIDIA GPUs [12] - This collaboration aims to enhance the scale and performance of AI models that can significantly advance human health [12] Group 3: Energy Solutions - Tapestry, a project under Alphabet's X, is working with NVIDIA to develop AI-powered products for a more reliable and sustainable electric grid [13][14] - The focus is on optimizing energy grid simulations and integrating new energy sources to meet the demands of data centers and AI [14] Group 4: AI Infrastructure Advancements - Google Cloud will be among the first to adopt NVIDIA's latest GB300 NVL72 and RTX PRO 6000 Blackwell Server Edition GPUs, enhancing AI performance [3][15] - The GB300 NVL72 offers 1.5 times more AI performance compared to its predecessor, with a 50 times increase in revenue opportunity for AI factories [16] Group 5: Open Model Optimization - Google DeepMind and NVIDIA are optimizing Gemma, a family of lightweight open models, to run efficiently on NVIDIA GPUs, enhancing accessibility for developers [7] - The collaboration also includes optimizing Gemini-based workloads on NVIDIA accelerated computing via Vertex AI [8]